Daratumumab (new scientific evidence (§ 14): newly diagnosed multiple myeloma, in combination with lenalidomide and dexamethasone for patients unsuitable for autologous stem cell transplantation)


  • Active Substance: Daratumumab
  • Name: Darzalex®
  • Therapeutic area: Multiple myeloma
  • Pharmaceutical company: Janssen-Cilag GmbH

Time table:

  • Start: 01.10.2021
  • Final decision by G-BA: 18.03.2022

Final decision:

  • Hint for a considerable additional benefit